Integrated BioPharma, Inc. (INBP) News
Track canonical SquawkNews coverage tagged to INBP, Integrated BioPharma, Inc.. This hub brings together deduplicated headlines about otc markets otcqx, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Integrated BioPharma, Inc. (INBP) FY26 Revenue Falls 19%, Turns to Loss
Integrated BioPharma reported FY26 revenue of $43.9M, down 19.3% YoY, and an operating loss of ~$2.7M vs. $2.0M income in FY25. Q4 revenue was $9.8M, down 31.0% YoY, with a net loss of ~$1.4M.Material DetailsContext by A
EARNINGS | Sep 25, 2026, 09:01 PM UTC
L
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
HILLSIDE, NJ / / September 25, 2026 / Integrated BioPharma, Inc. OTC:INBP (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026.Revenue for the quarter ended June 30,
EARNINGS | Sep 25, 2026, 09:01 PM UTC
L
INTEGRATED BIOPHARMA INC FY 2026: Revenue $43.87M, EPS ($0.09) — 10-K Summary
Integrated Biopharma Inc reported fiscal 2026 results with revenue of $43.87M, down from $54.35M a year earlier, producing a net loss of ($2.84M) and diluted EPS of ($0.09) — a year-over-year decline versus FY 2025 — acc
EARNINGS | Sep 25, 2026, 08:46 PM UTC